Protective effects of endothelin receptor A and B inhibitors against doxorubicin-induced cardiomyopathy

Biochemical Pharmacology

Volumn 94, Issue 2, 2015, Pages 109-129

  Schwebe, Matthias ^a   Ameling, Sabine ^a   Hammer, Elke ^a   Monzel, Judith V ^a   Bonitz, Karina ^a   Budde, Susanne ^a   Schult, Kathleen ^a   Oswald, Stefan ^a   Scheuch, Eberhard ^a   Grube, Markus ^a   Poesch, Axel ^a   Budde, Thomas ^a   Ewert, Ralf ^a   Schroeder, Henry W S ^a   Kroemer, Heyo K ^a   Bien Möller, Sandra ^a  

^a UNIVERSITY MEDICINE GREIFSWALD   (Germany)

Author keywords

Cardiomyopathy; Doxorubicin; Endothelin

Indexed keywords

ADENINE NUCLEOTIDE TRANSLOCASE; BOSENTAN; DOXORUBICIN; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; PROTEIN KINASE PIM 1; SITAXSENTAN; STAT3 PROTEIN; ANTINEOPLASTIC ANTIBIOTIC; CARDIOTONIC AGENT; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; DOXORUBICIN INDUCED CARDIOMYOPATHY; DRUG EFFICACY; ENERGY YIELD; GENE CONTROL; GENE EXPRESSION PROFILING; HEART FUNCTION; HEART MUSCLE CELL; HEART PROTECTION; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; CARDIOMYOPATHIES; CHEMICALLY INDUCED; DRUG EFFECTS;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOMYOPATHIES; CARDIOTONIC AGENTS; DOXORUBICIN; MALE; MICE; MICE, INBRED C57BL; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B;

EID: 84923868764     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2015.01.014     Document Type: Article

References (61)

1. R.B. Weiss The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 19 1992 670 686
2. M.F. Press, G. Sauter, M. Buyse, L. Bernstein, R. Guzman, A. Santiago, I.E. Villalobos, W. Eiermann, T. Pienkowski, M. Martin, N. Robert, J. Crown, V. Bee, H. Taupin, K.J. Flom, I. Tabah-Fisch, G. Pauletti, M.A. Lindsay, A. Riva, and D.J. Slamon Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy J Clin Oncol 29 2011 859 867
3. A. Marco, and F. Arcamone DNA complexing antibiotics: daunomycin, adriamycin and their derivatives Arzneimittelforschung 25 1975 368 374
4. J.R. Muindi, B.K. Sinha, L. Gianni, and C.E. Myers Hydroxyl radical production and DNA damage induced by anthracycline-iron complex FEBS Lett 172 1984 226 230
5. S.A. Murphree, T.R. Tritton, P.L. Smith, and A.C. Sartorelli Adriamycin-induced changes in the surface membrane of sarcoma 180 ascites cells Biochim Biophys Acta 649 1981 317 324
6. J.M. Berthiaume, and K.B. Wallace Adriamycin-induced oxidative mitochondrial cardiotoxicity Cell Biol Toxicol 23 2007 15 25
7. A. Ma, W. Zhang, and Z. Liu Effect of protection and repair of injury of mitochondrial membrane-phospholipid on prognosis in patients with dilated cardiomyopathy Blood Press Suppl 3 1996 53 55
8. F.S. Carvalho, A. Burgeiro, R. Garcia, A.J. Moreno, R.A. Carvalho, and P.J. Oliveira Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy Med Res Rev 34 2014 106 135
9. A.L. Ferreira, L.S. Matsubara, and B.B. Matsubara Anthracycline-induced cardiotoxicity Cardiovasc Hematol Agents Med Chem 6 2008 278 281
10. F. Brunner, C. Bras-Silva, A.S. Cerdeira, and A.F. Leite-Moreira Cardiovascular endothelins: essential regulators of cardiovascular homeostasis Pharmacol Ther 111 2006 508 531
11. M.M. Sayed-Ahmed, M.M. Khattab, M.Z. Gad, and A.M. Osman Increased plasma endothelin-1 and cardiac nitric oxide during doxorubicin-induced cardiomyopathy Pharmacol Toxicol 89 2001 140 144
12. P. Picard, P.J. Smith, J.C. Monge, J.L. Rouleau, Q.T. Nguyen, A. Calderone, and D.J. Stewart Coordinated upregulation of the cardiac endothelin system in a rat model of heart failure J Cardiovasc Pharmacol 31 Suppl. 1 1998 S294 S297
13. L.L. Yang, R. Gros, M.G. Kabir, A. Sadi, A.I. Gotlieb, M. Husain, and D.J. Stewart Conditional cardiac overexpression of endothelin-1 induces inflammation and dilated cardiomyopathy in mice Circulation 109 2004 255 261
14. S. Bien, A. Riad, C.A. Ritter, M. Gratz, F. Olshausen, D. Westermann, M. Grube, T. Krieg, S. Ciecholewski, S.B. Felix, A. Staudt, H.P. Schultheiss, R. Ewert, U. Volker, C. Tschope, and H.K. Kroemer The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy Cancer Res 67 2007 10428 10435
15. D. Marchant, Y. Dou, H. Luo, F.S. Garmaroudi, J.E. McDonough, X. Si, E. Walker, Z. Luo, A. Arner, R.G. Hegele, I. Laher, and B.M. McManus Bosentan enhances viral load via endothelin-1 receptor type-A-mediated p38 mitogen-activated protein kinase activation while improving cardiac function during coxsackievirus-induced myocarditis Circ Res 104 2009 813 821
16. R.G. Tilton, C.L. Munsch, S.J. Sherwood, S.J. Chen, Y.F. Chen, C. Wu, N. Block, R.A. Dixon, and T.A. Brock Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist Pulm Pharmacol Ther 13 2000 87 97
17. R.G. Landgraf, and S. Jancar Endothelin A receptor antagonist modulates lymphocyte and eosinophil infiltration, hyperreactivity and mucus in murine asthma Int Immunopharmacol 8 2008 1748 1753
18. P.J. Oliveira, and K.B. Wallace Depletion of adenine nucleotide translocator protein in heart mitochondria from doxorubicin-treated rats - relevance for mitochondrial dysfunction Toxicology 220 2006 160 168
19. G.A. Borillo, M. Mason, P. Quijada, M. Volkers, C. Cottage, M. McGregor, S. Din, K. Fischer, N. Gude, D. Avitabile, S. Barlow, R. Alvarez, S. Truffa, R. Whittaker, M.S. Glassy, A.B. Gustafsson, S. Miyamoto, C.C. Glembotski, R.A. Gottlieb, J.H. Brown, and M.A. Sussman Pim-1 kinase protects mitochondrial integrity in cardiomyocytes Circ Res 106 2010 1265 1274
20. J.A. Muraski, M. Rota, Y. Misao, J. Fransioli, C. Cottage, N. Gude, G. Esposito, F. Delucchi, M. Arcarese, R. Alvarez, S. Siddiqi, G.N. Emmanuel, W. Wu, K. Fischer, J.J. Martindale, C.C. Glembotski, A. Leri, J. Kajstura, N. Magnuson, A. Berns, R.M. Beretta, S.R. Houser, E.M. Schaefer, P. Anversa, and M.A. Sussman Pim-1 regulates cardiomyocyte survival downstream of Akt Nat Med 13 2007 1467 1475
21. T. Shirogane, T. Fukada, J.M. Muller, D.T. Shima, M. Hibi, and T. Hirano Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis Immunity 11 1999 709 719
22. T.K. Kundu, R. Hille, M. Velayutham, and J.L. Zweier Characterization of superoxide production from aldehyde oxidase: an important source of oxidants in biological tissues Arch Biochem Biophys 460 2007 113 121
23. A.I. Abdelaziz, I. Pagel, W.P. Schlegel, M. Kott, J. Monti, H. Haase, and I. Morano Human atrial myosin light chain 1 expression attenuates heart failure Adv Exp Med Biol 565 2005 283 292
24. M. Descorbeth, and M.B. Anand-Srivastava Role of vasoactive peptides in high glucose-induced increased expression of Galphaq/11 proteins and associated signaling in vascular smooth muscle cells Can J Physiol Pharmacol 88 2010 331 340
25. K. Kunisada, S. Negoro, E. Tone, M. Funamoto, T. Osugi, S. Yamada, M. Okabe, T. Kishimoto, and K. Yamauchi-Takihara Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy Proc Natl Acad Sci U S A 97 2000 315 319
26. W.C. Claycomb, N.A. Lanson Jr.; B.S. Stallworth, D.B. Egeland, J.B. Delcarpio, A. Bahinski, and N.J. Izzo Jr. HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte Proc Natl Acad Sci U S A 95 1998 2979 2984
27. C.F. Opitz, R. Ewert, W. Kirch, and D. Pittrow Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter? Eur Heart J 29 2008 1936 1948
28. M. Okada, and M. Nishikibe BQ-788, a selective endothelin ET(B) receptor antagonist Cardiovasc Drug Rev 20 2002 53 66
29. K. Shan, A.M. Lincoff, and J.B. Young Anthracycline-induced cardiotoxicity Ann Intern Med 125 1996 47 58
30. J.N. Cohn, G. Johnson, S. Ziesche, F. Cobb, G. Francis, F. Tristani, R. Smith, W.B. Dunkman, H. Loeb, and M. Wong A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure N Engl J Med 325 1991 303 310
31. B. Pitt, F. Zannad, W.J. Remme, R. Cody, A. Castaigne, A. Perez, J. Palensky, and J. Wittes The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators N Engl J Med 341 1999 709 717
32. B. Pieske, B. Beyermann, V. Breu, B.M. Loffler, K. Schlotthauer, L.S. Maier, S. Schmidt-Schweda, H. Just, and G. Hasenfuss Functional effects of endothelin and regulation of endothelin receptors in isolated human nonfailing and failing myocardium Circulation 99 1999 1802 1809
33. P. Molenaar, G. O'Reilly, A. Sharkey, R.E. Kuc, D.P. Harding, C. Plumpton, G.A. Gresham, and A.P. Davenport Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium Circ Res 72 1993 526 538
34. M. Chun, H.Y. Lin, Y.I. Henis, and H.F. Lodish Endothelin-induced endocytosis of cell surface ETA receptors. Endothelin remains intact and bound to the ETA receptor J Biol Chem 270 1995 10855 10860
35. F.E. Strachan, J.C. Spratt, I.B. Wilkinson, N.R. Johnston, G.A. Gray, and D.J. Webb Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men Hypertension 33 1999 581 585
36. D.E. Kohan, N.F. Rossi, E.W. Inscho, and D.M. Pollock Regulation of blood pressure and salt homeostasis by endothelin Physiol Rev 91 2011 1 77
37. H. Karaki, S.A. Sudjarwo, and M. Hori Novel antagonist of endothelin ETB1 and ETB2 receptors, BQ-788: effects on blood vessel and small intestine Biochem Biophys Res Commun 205 1994 168 173
38. A.F. Leite-Moreira, and C. Bras-Silva Inotropic effects of ETB receptor stimulation and their modulation by endocardial endothelium, NO, and prostaglandins Am J Physiol Heart Circ Physiol 287 2004 H1194 H1199
39. I. Braasch, and M. Schartl Evolution of endothelin receptors in vertebrates Gen Comp Endocrinol 209C 2014 21 34
40. K.T. Kivisto, H.K. Kroemer, and M. Eichelbaum The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions Br J Clin Pharmacol 40 1995 523 530
41. C.Q. Xia, and P.G. Smith Drug efflux transporters and multidrug resistance in acute leukemia: therapeutic impact and novel approaches to mediation Mol Pharmacol 82 2012 1008 1021
42. C. Weber, R. Gasser, and G. Hopfgartner Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects Drug Metab Dispos 27 1999 810 815
43. A.C. Widlitz, R.J. Barst, and E.M. Horn Sitaxsentan: a novel endothelin-A receptor antagonist for pulmonary arterial hypertension Expert Rev Cardiovasc Ther 3 2005 985 991
44. J. Weiss, M. Herzog, and W.E. Haefeli Differential modulation of the expression of important drug metabolising enzymes and transporters by endothelin-1 receptor antagonists ambrisentan and bosentan in vitro Eur J Pharmacol 660 2011 298 304
45. Y. Mano, T. Usui, and H. Kamimura Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance-associated protein 2 Biopharm Drug Dispos 28 2007 13 18
46. S. Zhou, L.J. Heller, and K.B. Wallace Interference with calcium-dependent mitochondrial bioenergetics in cardiac myocytes isolated from doxorubicin-treated rats Toxicol Appl Pharmacol 175 2001 60 67
47. H.P. Schultheiss, P.A. Berg, and M. Klingenberg Inhibition of the adenine nucleotide translocator by organ specific autoantibodies in primary biliary cirrhosis Clin Exp Immunol 58 1984 596 602
48. B.H. Graham, K.G. Waymire, B. Cottrell, I.A. Trounce, G.R. MacGregor, and D.C. Wallace A mouse model for mitochondrial myopathy and cardiomyopathy resulting from a deficiency in the heart/muscle isoform of the adenine nucleotide translocator Nat Genet 16 1997 226 234
49. T. Walther, C. Tschope, A. Sterner-Kock, D. Westermann, S. Heringer-Walther, A. Riad, A. Nikolic, Y. Wang, L. Ebermann, W.E. Siems, M. Bader, M. Shakibaei, H.P. Schultheiss, and A. Dorner Accelerated mitochondrial adenosine diphosphate/adenosine triphosphate transport improves hypertension-induced heart disease Circulation 115 2007 333 344
50. H. Zhang, G. Xue, W. Zhang, L. Wang, H. Li, L. Zhang, F. Lu, S. Bai, Y. Lin, Y. Lou, C. Xu, and Y. Zhao Akt and Erk1/2 activate the ornithine decarboxylase/polyamine system in cardioprotective ischemic preconditioning in rats: the role of mitochondrial permeability transition pores Mol Cell Biochem 2014
51. S. Maruyama, R. Shibata, K. Ohashi, T. Ohashi, H. Daida, K. Walsh, T. Murohara, and N. Ouchi Adiponectin ameliorates doxorubicin-induced cardiotoxicity through Akt protein-dependent mechanism J Biol Chem 286 2011 32790 32800
52. H.J. Hong, J.C. Liu, P.Y. Chen, J.J. Chen, P. Chan, and T.H. Cheng Tanshinone IIA prevents doxorubicin-induced cardiomyocyte apoptosis through Akt-dependent pathway Int J Cardiol 157 2012 174 179
53. P.Y. Bourillot, I. Aksoy, V. Schreiber, F. Wianny, H. Schulz, O. Hummel, N. Hubner, and P. Savatier Novel STAT3 target genes exert distinct roles in the inhibition of mesoderm and endoderm differentiation in cooperation with Nanog Stem Cells 27 2009 1760 1771
54. X.M. Pei, B.Y. Yung, S.P. Yip, M. Ying, I.F. Benzie, and P.M. Siu Desacyl ghrelin prevents doxorubicin-induced myocardial fibrosis and apoptosis via the GHSR-independent pathway Am J Physiol Endocrinol Metab 306 2014 E311 E323
55. Y. Octavia, C.G. Tocchetti, K.L. Gabrielson, S. Janssens, H.J. Crijns, and A.L. Moens Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies J Mol Cell Cardiol 52 2012 1213 1225
56. D.E. Clouthier, K. Hosoda, J.A. Richardson, S.C. Williams, H. Yanagisawa, T. Kuwaki, M. Kumada, R.E. Hammer, and M. Yanagisawa Cranial and cardiac neural crest defects in endothelin-A receptor-deficient mice Development 125 1998 813 824
57. Y. Kurihara, H. Kurihara, H. Suzuki, T. Kodama, K. Maemura, R. Nagai, H. Oda, T. Kuwaki, W.H. Cao, and N. Kamada Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1 Nature 368 1994 703 710
58. R.M. Kedzierski, P.A. Grayburn, Y.Y. Kisanuki, C.S. Williams, R.E. Hammer, J.A. Richardson, M.D. Schneider, and M. Yanagisawa Cardiomyocyte-specific endothelin A receptor knockout mice have normal cardiac function and an unaltered hypertrophic response to angiotensin II and isoproterenol Mol Cell Biol 23 2003 8226 8232
59. A.P. Davenport, and R.E. Kuc Down-regulation of ETA receptors in ETB receptor-deficient mice J Cardiovasc Pharmacol 44 Suppl. 1 2004 S276 S278
60. R.M. Rapoport, and M. Zuccarello Endothelin(A)-endothelin(B) receptor cross talk in endothelin-1-induced contraction of smooth muscle J Cardiovasc Pharmacol 60 2012 483 494
61. V. McLaughlin, M. Humbert, G. Coghlan, P. Nash, and V. Steen Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis Rheumatology (Oxford) 48 Suppl. 3 2009 iii25 iii31